Learn more about implementing the TruSight Oncology 500 ctDNA assay to enable comprehensive genomic profiling (CGP) from circulating tumor DNA in this seminar recorded at AMP 2019. Dr. Biswajit Das of the Frederick National Laboratory (FNL) / MoCHA and Dr. Stephanie Hastings of Q2 Solutions discuss their analytical validation studies using a pre-released version of TruSight Oncology 500 ctDNA assay in liquid biopsy samples.
From this team of early access users, you will hear about:
• Specificity and sensitivity of TruSight™ Oncology 500 ctDNA in detecting low level of variants in circulating tumor DNA
• Ability of this single assay to assess multiple variant classes with coverage of key biomarkers in guidelines and clinical trials
• Their plans to incorporate TruSight Oncology 500 ctDNA into future clinical trials and research studies